Deeptech factory

Revolutionizing biodetection

Kimialys develops and sells disruptive surface chemistries for biosensors, increasing their sensitivity and specificity, and opening up new possibilites in the in vitro diagnostics.

CEO : Cyril Gilbert

Creation : october 2020

Headcount : 13

Location : Paris/Paris-Saclay

Market(s) : Lateral Flow Assay / Drug Discovery

#Nanoparticles #Biochips #Chemistry #Diagnostics


Built on 10 years of academic research, Kimialys’ patented surface chemistry can be applied on gold nanoparticules and biochips. Its double action removes background noise by protecting the surface against non-specific interactions, and improves sensitivity by optimizing the ligand density, repartition and orientation towards the target biomolecules.


  • Surface chemistry K-One
  • Functionalized gold nanoparticles and biochips
  • Biophysical analysis (screening, characterization)


Kimialys first addresses developers and manufacturers of Rapid Diagnostic Tests. As a technology provider, Kimialys help them increase the performance of their lateral flow assay while lowering their cost, using K-One-functionalized nanoparticles.
Kimialys also offers biophysical analysis services to pharmaceutical laboratories in the drug discovery phase, providing reliable screening and characterization of biomolecules. The Kimialys team draws on its extensive expertise in SPR (Surface Plasmon Resonance) measurements, coupled with its innovative chip-based functionalization, to deliver unprecedented results.


Kimialys opens up new possibilities in the diagnostic, pharmaceutical and life science industries, thanks to a unique combination of benefits:
– Sensitivity gains of up to x10;
– Optimal specificity (no background noise);
– Cost-reduction of the biodetection (regeant consumption reduced by 50%);
– Efficient in complex sample (serum, saliva, urine), without any difference with buffer solutions;
– Compatible with any biosensor using gold nanoparticles and biochips.